These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 26471036)

  • 1. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
    Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
    Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic evaluation of screening for colorectal cancer: Case of Iran.
    Barouni M; Ghaderi H; Shahmoradi MK
    Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal occult blood testing when colonoscopy capacity is limited.
    Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
    J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
    Lee KS; Park EC
    Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Análisis de Costo-Efectividad de las Estrategias de Tamización de Cáncer Colorrectal en Colombia.
    Pinzon Florez CE; Rosselli D; Gamboa Garay OA
    Value Health Reg Issues; 2012 Dec; 1(2):190-200. PubMed ID: 29702900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.